|
|
Article: Arginetix Closes $10.75 Million Series A Financing.
- Article from:
- Real Estate & Investment Business
- Article date:
- October 24, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Arginetix, Inc. announced it has closed a $10.75 million Series A financing. The company is developing small molecule inhibitors of the enzyme arginase for the treatment of endothelial dysfunction, including pulmonary arterial hypertension, atherosclerosis and asthma.
The financing was co-led by Quaker BioVentures and MedImmune Ventures, a wholly owned venture capital fund of the AstraZeneca Group. Maryland Health Care Product Development Corp., Osage University Partners, Red Abbey Venture Partners, and company co-founder Acidophil LLC also participated in the round.
Arginetix will utilize this financing for further discovery and to continue development ...